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additional 6% to 11% of variance), however carer characteristics only emerged as a 
significant predictor of the health burden scale (11% of explained variance). Key indi-
vidual predictor variables of burden domains included patients’ general health sta-
tus, presence of a stoma, and the time costs associated with care. ConClusions: 
These results highlight the need to recognise the role that various factors play in 
determining carer burden. While certain aspects of carer characteristics influence 
this, patient health and care-related activities have the most significant impact 
pointing to a need to deliver effective support to those most at risk of carer burden.
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INvestIgatINg the use of PersoNalIsed MedICINe IN CaNCer trIals – aN 
uPdate
Hamilton K.A., Wilson T.
Costello Medical Consulting Ltd., Cambridge, UK
objeCtives: Personalised medicine continues to be a hot topic in health care evalu-
ation, particularly in diseases where response to therapy within the patient popula-
tion is often heterogenous. The results of an analysis previously presented at ISPOR 
showed that the proportion of cancer trials investigating personalised medicine 
rose 7-fold between 2000 and 2010. However, in 2011, this trend appeared to have 
reached a plateau, with the proportion of cancer trials considering personalised 
medicine settling at around 15-20%. The aim of this study was to update the previous 
research to take account of the proportion of cancer trials which included personal-
ised medicine between 2012 and 2013, inclusive, to assess whether this pattern has 
changed in more recent years. Methods: Terms including ‘diagnostic’, ‘prognostic’ 
and ‘biomarker’ were used to search ClinicalTrials. gov for all interventional cancer 
trials which started between 2012 and 2013 and considered the use of individualised 
medicine. These trials were then compared to those of all interventional cancer tri-
als listed on ClinicalTrials. gov starting in the same period. Results: Of all cancer 
trials analysed between 2000 and 2013, inclusive, 3,664 of 25,203 (14.5%) consid-
ered personalised medicine. Although the previous analysis showed a substantial 
increase in this proportion between 2000 and 2010, this trend does not appear to 
continue into the current decade. The proportion of trials considering personalised 
medicine identified in this update was consistent with that seen in 2011, with 17.7% 
of trials in 2012 and 18.8% in 2013 considering personalised medicine, perhaps sig-
nifying a lack of further increase in research interest. ConClusions: Surprisingly, 
in spite of the apparent drive and enthusiasm for the use of personalised medicine 
within the medical community, these results indicate that the proportion of such 
trials may have reached a plateau. Therefore, this might suggest that cancer research 
is continuing to focus on traditional, non-personalised interventions.
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the role of PrIor Breast CaNCer dIagNosIs IN artICulatINg 
exPeCtatIoNs for reCoNstruCted Breast aPPearaNCe
Scott A.M.1, Lawson J.L.2, Mazza M.C.3, Rubin L.R.3
1Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2Yeshiva University, Bronx, NY, 
USA, 3The New School for Social Research, New York, NY, USA
objeCtives: Women who undergo mastectomy, whether due to a first-time breast 
cancer diagnosis or recurrence, are often presented with the option of breast recon-
struction. Decisions whether to undergo reconstruction are informed by women’s 
surgery expectations, which develop based on many factors, including past knowl-
edge and experience. The aim of this study was to examine the impact of previous 
breast cancer diagnosis on a women’s approach to expectation-identification of their 
reconstructed breast appearance. Methods: This study was performed using cross-
sectional data as part of a larger field-test. Expectations scales of the BREAST-Q PRO 
were administered in a clinical setting to breast cancer patients seeking immediate 
breast reconstruction. Responses were categorized into specific (unlikely, somewhat 
likely, very likely) or vague expectations (don’t know) as the dependent variable. The 
independent variable was defined as previous or primary diagnosis. Chi Square and 
one-way ANOVA were performed using SPSS22. Results: The study sample (n = 62; 
response rate, 66%) was characterized by a mean age of 49.6 ± 9.2 years, 82.3% married, 
77.4% employed and 79.0% Caucasian. Twenty-three (37.1%) had a history of previous 
breast cancer diagnosis without mastectomy. Women who had previous breast cancer 
diagnosis were more likely to select a specific expectation in response to what their 
new breast (s) would look like in the mirror clothed (ETA squared; 0.11, P= 0.011) and 
unclothed (ETA squared; 0.09, P= 0.017) one year after reconstruction. ConClusions: 
Expectancies guide perception, so that people tend to focus on events that are congru-
ent with their expectations. In our study, women undergoing breast reconstruction 
were more likely to identify a specific expectation about the appearance of their 
reconstructed breast if they had been previously diagnosed with breast cancer. More 
research is needed to determine additional factors that may mediate the develop-
ment of preoperative surgical expectations. Such information will aid in facilitating 
patient-physician communication.
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NICe restrICtIveNess CoMPared to the Market authorIzatIoN IN 
oNCology aNd NoN-oNCology revIews
Jaksa A., Westbrook L., Rubinstein E., Daniel K., Ho Y.S.
Context Matters, Inc., New York, NY, USA
objeCtives: To determine how often NICE recommendations are more restric-
tive than market authorizations in oncology reviews compared to non-oncology 
reviews. Methods: 161 NICE Technology Appraisal decisions from 2007-2013 were 
evaluated; 95 non-oncology and 66 oncology reviews. For each generic drug included 
in a review, the corresponding brand and market authorization was retrieved from 
the EMA or MHRA. NICE positive decisions were compared to the market authoriza-
tions. Any decision that included language that restricted the population eligible for 
treatment or reimbursement for a given therapy was categorized as “recommend 
with restrictions.” NICE positive decisions that were not more restrictive than the 
market authorizations were categorized as “recommend.” Negative decisions were 
categorized as “do not recommend.” Results: Oncology reviews were more likely to 
By comparison, only 7/88 (8%) of NICE-approved cancer appraisals have been subject 
to restrictions in addition to the label. ConClusions: Access to anti-cancer drugs 
under the CDF tends to be more restrictive than those approved by NICE. Thus, attain-
ing NICE approval for CDF-approved drugs could broaden clinical access as well as 
ensuring reimbursement after the fund is due to close in 2016. Nevertheless, the CDF 
does provide a formal mechanism under which reimbursement can be provided for 
off-label use of cancer drugs, which NICE will not consider.
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aPPlICatIoN of threshold value for Cost-effeCtIveNess IN 
reCoMMeNdatIoNs Issued By ageNCy for health teChNology 
assessMeNt IN PolaNd for CaNCer drug teChNologIes
Zawodnik A., Matusewicz W.
Agency for Health Technology Assessment in Poland (AOTM), Warsaw, Poland
objeCtives: To analyse HTA recommendations for cancer drug technologies issued 
by Agency for Health Technology Assessment (AHTAPol) in Poland and to verify if 
official threshold value for cost-effectiveness is respected. Methods: The review 
of HTA recommendations concerning cancer technologies issued by AHTAPol in the 
period from January 2012 to March 2014 was preformed. The classification of HTA 
recommendations based on Raftery’s approach labeling them as positive, positive 
with major or minor restriction and negative was conducted. Decisions and ICURs 
values from each recommendation were compared to the official threshold value for 
cost-effectiveness (in Poland defined as 3xGDP for each year) and defined whether 
the ICUR value is either above or below the official threshold. Other aspects of 
recommendations, such as criterion for decision, type of RSS implemented and 
reasons for restrictions were also analysed. Results: In the studied period AHTAPol 
issued 46 recommendations for 35 different cancer drugs (due to the multiplied 
recommendations for 4 drugs). After review, 32 recommendations with calculated 
ICUR (with Risk Sharing Scheme (RSS) if implemented) were included in the analy-
sis. For 11 of 13 negative recommendations ICUR values were placed above offi-
cial AHTAPol’s threshold. For 7 of 11 positive recommendations ICUR values were 
placed below threshold. On the other hand, for 5 of 7 positive recommendations 
with major restriction ICUR values were placed above official threshold. However, 
restrictions were related to the unacceptable cost-effectiveness. The same analysis 
for the ICUR values without implementation of RSS was conducted to compare the 
results. ConClusions: The official threshold values set in AHTAPol are respected 
in the majority of decisions for cancer drugs. Cost-effectiveness is one of the most 
important criterion of decisions made by AHTAPol. Clinical effectiveness, safety and 
specificity of end-of-life extending medicines were also considered.
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PrICe CoNtrol of out-PatIeNt CaNCer drugs IN BulgarIa, 2010-2011: 
refereNCe Based PrICINg aNd PuBlIC teNders versus refereNCe Based 
PrICINg oNly
Djambazov S.N.1, Vekov T.Y.2, Petrov D.3
1Cancer clinics Doc Dr Valentina Tsekova, Sofia, Bulgaria, 2Medical University Pleven, Pleven, 
Bulgaria, 3Bulgarian Medical Union, Sofia, Bulgaria
objeCtives: To compare drug prices and public expenditure of out-patient cancer 
drugs between two consecutive periods: reference based pricing (RBP) and public 
tendering at MoH in 2010 and RBP only in a positive drug list (PDL) at the National 
Health Insurance Fund (NHIF) in 2011. Methods: We compared the prices of the 40 
products, which are used in out-patient setting. We used public documents like ten-
der results from 2010 MoH tender and reimbursement list of NHIF in 2011. Results: 
70% of the products (n= 28) were with higher prices, 20% had no price change (n= 8) 
and 10% (n= 4) had lower prices in 2011. In 2010, 15% (n= 6) had 50% lower prices 
than same products’ prices in the PDL in 2011. For 10% of the products (n= 4) in 
2010, after tendering, the MoH paid higher prices than the registered prices after 
RBP. These were patented products, without generic competition. In 2011, NHIF paid 
BGN 18.591.365 for these 40 drugs. For the same quantities, with MoH 2010 prices, 
the public expenditure could be BGN 10.788.430 (42% lower). ConClusions: Public 
tendering achieved lower prices than RBP alone. For patented products, without 
generic competition, tendering is not the ultimate solution. Tendering should be 
used with caution, as it can drive some producers out of the market and create 
non-competitive environment with counter-productive results. Frequent changes 
of the laws and regulations, without budget impact analysis, is like gambling. Long-
term national drug pricing policy is hardly needed and should be strictly followed.
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uNderstaNdINg CaregIver BurdeN IN ColoreCtal CaNCer: what role 
do PatIeNt aNd Carer faCtors Play?
Maguire R.1, Hanly P.1, Hyland P.1, Sharp L.2
1National College of Ireland, Dublin, Ireland, 2National Cancer Registry Ireland, Cork, Ireland
objeCtives: This study aimed to explore the key determinants of caregiver burden 
in colorectal cancer (CRC) carers. Specifically we analysed the effect of (i) patient 
health (ii) care-related activities, and (iii) carer characteristics, as predictors of four 
distinct aspects of carer burden. Methods: 495 CRC survivors (response rate = 39%) 
diagnosed 2007-2009 completed a questionnaire which collected information on 
socio-demographic characteristics, as well as disease and treatment-related factors. 
General health status was measured using the EORTC QLQ30.228 of these survivors 
indicated that they had informal carers who were then sent a questionnaire includ-
ing questions on socio-demographic factors, health status and care-related costs 
as well as the Caregiver Reaction Assessment (CRA) scale. Hierarchical multiple 
regression analysis was used to assess the impact of patient factors, care-related 
activities and carer characteristics on four burden elements within the CRA (family 
support, finances, schedule, and health). Results: 153 carers completed the carer 
questionnaire and were included in the analysis with their corresponding patients. 
Patient characteristics and disease-related factors were the strongest predictor of 
all four aspects of caregiver burden ranging from 14% to 22% of explained variance. 
Care-related activities also significantly predicted burden scores (explaining an 
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for 40% of decisions, were compared with those of three major HTA agencies: CADTH, 
NICE and PBAC. HTA reports and meeting transcripts were analysed and categorised 
by date, therapy area, decision, rationale, and pricing decision. Resubmissions or those 
not assessed by the western HTA agencies were excluded. Results: A total of 65 NHI 
reports were identified. Of these 26 reported decisions on oncology or cardiovascular 
drugs, 12 were excluded (3 resubmissions, 9 not reviewed by the other agencies). Prior 
to 2GNHI, 4 out of 5 decisions were positive, or 80% approval rate, while after, only 
4 out of 9 were positive, a 44% approval rate. Prior to 2GNHI, all NHI reimbursement 
decisions identified (6) matched CADTH, NICE, and PBAC. After 2GNHI, only 6/9 or 
66% matched. Clinical effectiveness and budget impact were most cited in reim-
bursement rejections. For example Zytiga, NHI appreciated the cost-effectiveness 
but stated budget impact was too high, issuing a negative recommendation, contrary 
to the other agencies. Interestingly, a ‘local’ product was recommended for limited 
reimbursement even though budget impact was high. ConClusions: Since imple-
mentation of Taiwan’s NHI reforms in January 2013, cardiovascular and oncology drug 
approvals dropped by 36% and agreements with western agencies down 34%, placing 
an emphasis on budget impact. However, this analysis was constrained by its small 
sample size, and limited therapy areas.
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exPaNded data sets for hta deCIsIoN-MakINg IN oNCology: do they 
helP to aChIeve PosItIve aPPraIsals?
Chadda S.1, Mbanya Z.1, Gielen V.2, Chandler T.1
1PHMR Associates, Newcastle upon Tyne, UK, 2PHMR Associates, London, UK
objeCtives: Phase III, randomised controlled trials remain the gold standard 
for health technology assessment (HTA) submissions. Data sets may be sup-
plemented with other sources (e.g. Phase II trials, observational studies, mixed 
treatment comparisons). However, the influence of expanded data sets on HTA 
appraisals is unclear. Methods: We reviewed recent National Institute for 
Health and Care Excellence (NICE; England and Wales) oncology drug submissions 
to determine the frequency and type of expanded data sets. We then evaluated 
the influence of expanded data on agency decisions. A similar review of submis-
sions to the Australian Pharmaceutical Benefits Advisory Committee (PBAC) was 
performed. Results: There were 30 relevant appraisals on the NICE website 
covering a range of cancer types. Of these, 14/30 made use of expanded data sets 
featuring Phase II trials, observational studies, meta-analyses and/or mixed treat-
ment comparisons among other sources. Reasons for using expanded data sets 
included: agency concerns over Phase III studies, lack of long-term or head-to-head 
data and limited Phase III data. Where additional data were included, around one 
third (5/14 cases, 35.7%; 5/30 [16.7%] overall) appeared to have directly influenced 
the final decision. Overall, positive appraisals were less frequent for submissions 
that featured expanded data sets compared with submissions featuring Phase III 
data only (2/14 [14.3%] versus 9/16 [56.3%]). Comparable to NICE, 2/10 (20%) of PBAC 
submissions were influence by expanded data sets, although cost-effectiveness data 
were crucial for PBAC approval overall. ConClusions: We found that expanded 
data sets feature in nearly half of recent NICE oncology HTA assessments. However, 
additional data appeared to influence only one in five appraisals by NICE and PBAC. 
Expanded data sets have a place in contributing to HTA decision making, but overall, 
rigorous Phase III RCT data remain essential to obtaining a positive HTA appraisal.
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the lIfe aNd death of the eNd of lIfe treatMeNt aPPraIsal CrIterIa 
IN NICe teChNology aPPraIsals?
Kiss Z.1, Muszbek N.2, Benedict A.1
1Evidera, Budapest, Hungary, 2Evidera, London, UK
objeCtives: Since January 2009, NICE in the UK allows end of life (EOL) treatments 
to exceed the upper end (£30,000/QALY) of the threshold range for incremental 
cost-effectiveness ratios (ICERs) by using higher weights for EOL life-years. With 
discussions surrounding the concept and implementation, and the introduction of 
the value based assessment framework, the aim of this study was to review NICE 
technology appraisals (TAs) in oncology to assess the interpretation, implementa-
tion and implications of the criteria. Methods: All completed TAs in oncology 
since 2009 were searched. When multiple submissions of the same TA were made, 
the latest were selected. Data were extracted to capture details of the appraisal 
(e.g. treatment, indication and decision), the consideration of the five different 
EOL criteria (applicability, interpretation, effect on the decision) and the method 
of implementation (weighting, threshold). Results: 61 TAs, including six multi-
ple technology appraisals, assessing 71 technologies were reviewed. EOL criteria 
were considered in 40 TAs covering 44 technologies. EOL weighting was considered 
appropriate for 36% of technologies. Most technologies fulfilled the criterion of 
< 24 month life expectancy (rejected in 14%), extension of life by ≥ 3 months or 
robustness of its calculation was the most common cause of rejection (32%/25% 
respectively). These criteria were inconsistently applied, using different methods 
(e.g. medians, restricted means from extrapolation, means from trial or model). The 
criterion of small population favoured technologies with limited indication (rejec-
tion 20%). Earlier TAs presented weight calculations, while later TAs only presented 
ICERs. ConClusions: Although aiming for greater transparency, the criteria left 
a large scope for interpretation in the decision making. Also, with the emphasis 
from applying higher weights to EOL life-years shifting to a differential threshold 
for certain indications, the original idea of considering wider societal preferences 
seem to have been neglected, that the new guidance should remedy.
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aPPlICaBIlIty of euNethta relatIve effeCtIveNess assessMeNt of 
PazoPaNIB for NatIoNal assessMeNts
Kleijnen S.1, Leufkens H.G.M.2, Boer A.2, Goettsch W.3, Fathallah M.2
1Zorginstituut Nederland, Diemen, The Netherlands, 2University of Utrecht, Utrecht, The 
Netherlands, 3National Health Care Institute (ZIN) and EUnetHTA Partner, Diemen, The 
Netherlands
be issued a “do not recommend” decision than non-oncology reviews (56% vs. 16%, 
p< . 001). Over time, there was no significant trend in rates of “do not recommend” 
decisions for non-oncology reviews and oncology reviews, though rates of “do not 
recommend” decisions have increased for oncology reviews since 2008. There were no 
differences in the rates of “recommend” and “recommend with restriction” decisions 
between oncology and non-oncology reviews (p= . 87). Over time there was a signifi-
cant decrease in the rates of “recommend with restrictions” decisions for oncology 
reviews (p= . 07), but no statistical trend in non-oncology reviews. ConClusions: 
NICE was more likely to issue a “do not recommend” decision for oncology reviews 
than for non-oncology reviews, but there was no difference in the overall rates of 
“recommend with restrictions” decisions. Over time, NICE appears to be replacing 
“recommend with restriction” decisions with “do not recommend” decisions in oncol-
ogy reviews, but this did not pass traditional significance levels.
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systeMatIC revIew of eCoNoMIC evaluatIoNs IN CaNCerology IN 
BrazIl BetweeN 1980 aNd 2013
Yuba T.Y.1, Decimoni T.C.1, Leandro R.1, Campolina A.G.2, Soarez P.1
1Sao Paulo University, São Paulo, Brazil, 2Cancer Institute of the State of São Paulo, Sao Paulo, 
Brazil
Nowadays, economic evaluation has been increasingly used in health care decision-
making in Brazil. The Brazilian economic evaluation literature in cancerology is 
unknown. objeCtives: This systematic review aims to identify and characterize 
the economic evaluation studies in cancerology conducted in Brazil. Methods: 
Ten online databases (MEDLINE (PubMed), EMBASE, Latin American and Caribbean 
Literature on Health Sciences Database (LILACS), Scientific Electronic Library Online 
(SciELO), NHS Economic Evaluation Database (NHS EED), HTA Database (Centre 
for Reviews and Dissemination (CRD)), Biblioteca Virtual em Saúde Economia da 
Saúde (BVS ECOS), SCOPUS, Web of Science, and the Sistema de Informação da Rede 
Brasileira de Avaliação de Tecnologias em Saúde (SISREBRATS) were systematically 
searched. We also performed manual search. We selected partial and full economic 
evaluation studies in cancerology, where at least one of the authors was affiliated 
to a Brazilian institution. Two authors performed study selection and data extrac-
tion independently. Disagreements were resolved through discussion or through 
consultation with a third reviewer. The study characteristics were summarized in 
figures and summary tables. Results: A total of 11946 records were identified. Fifty 
six articles met inclusion criteria, of these, 33 (59%) were a full and 23 (41%) were 
a partial economic evaluation. The cost-effectiveness analysis was the most used 
(27%). There was an increase in the number of publications over the years, especially 
after 2006. Researchers from the Southeast region of Brazil were responsible for the 
majority of the publications (82%). Cancers most frequently studied were breast can-
cer (37%), followed by cervical cancer (16%), lung cancer (12%) and colorectal cancer 
(9.0%). The technologies most studied were medications (34%). ConClusions: The 
expansion of the economic analysis literature could be explained by the growing 
demand for HTA studies by the National Policy for Health Technology Assessment 
in Brazil that may have stimulated the scientific production in this area.
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health teChNology assessMeNts IN oNCology: CrIzotINIB Case study
Thivolet M.1, Kornfeld A.1, Toumi M.2
1Creativ-Ceutical, Paris, France, 2University Aix-Marseille, Marseille, France
objeCtives: Crizotinib (Xalkori®) was approved for the treatment of adults with 
non-small cell lung cancer (NSCLC). The objective of this study was to illustrate the 
divergence of Health Technology Assessments in oncology by comparing the deci-
sions of the National Institute for Health and Care Excellence (NICE), the Federal 
Joint Committee (G-BA) and French National Authority for Health (HAS). Methods: 
Crizotinib’s pivotal trial (Study 1007) was analysed. NICE, G-BA and HAS reports 
were reviewed, decisions’ drivers identified and final decisions compared. Results: 
Study 1007 was a randomised open-label trial comparing crizotinib with chemo-
therapy in patients with ALK+ advanced NSCLC and who had failed one chemo-
therapy regimen. The primary endpoint was progression-free survival (PFS) and 
overall survival (OS) was a secondary endpoint. While treatment with crizotinib 
increased significantly the PFS (4.7 months) no significant improvement in OS was 
observed versus chemotherapy group (OS interim analysis). Some quality of life 
(QoL) items (e.g. chest pain, dyspnea, fatigue) were improved within the crizotinib 
group. Even though no improvement in the OS was shown, the G-BA assessed the 
crizotinib benefit as considerable based on the improvement of QoL and morbidity 
decrease. The HAS also granted crizotinib an improvement in actual benefit of III 
based on the improvements in the PFS and QoL. However, the significant gain in PFS 
was not sufficient to get positive guidance from NICE. Indeed, NICE did not recom-
mend the use of crizotinib due to the uncertainties surrounding the OS: interim OS 
data and high rate of patients “crossing-over” from standard therapy to crizotinib 
arm. ConClusions: Cross-over has become a real obstacle to appreciate oncology 
product value. While an additional benefit can be granted based on improvement 
in PFS plus morbidity and QoL results in Germany and France, products supported 
solely by an increased PFS and no change in OS may face access barriers in England.
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IMPaCt of health Care reforM oN drug reIMBurseMeNt deCIsIoN-
MakINg IN taIwaN
Lai L.1, Eccles T.1, Heemstra L.2, Van Engen A.2
1Quintiles Consulting, Reading, UK, 2Quintiles Consulting, Hoofddorp, The Netherlands
objeCtives: Taiwan is considered a challenging market to access, largely due to strict 
pricing and reimbursement policies. To assess the impact of health insurance reforms 
introduced in January 2013 (Second Generation National Health Insurance or 2GNHI), 
Taiwan reimbursement decisions and granted prices before and after the introduction 
were compared with major western countries. Methods: Publications of Taiwan 
NHI from March 2011 to February 2014 were searched and reimbursement decisions 
identified. The largest therapy areas, oncology and cardiovascular, which accounted 
